Summary
29 / 100 · Bulios Score
What speaks for it
- It has no debt and holds $11.3M in cash.
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $8.71M.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 2
- Sell 0
No analyst has published a price target.
60% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Grant 100%
By region
The company reports no revenue by region.
Grant brings in 100% of revenue.
Segments in detail